Medscape2d
Dipeptidyl Peptidase-4 Inhibitors: Clinical Data and Clinical Implications
Several DPP-4 inhibitors are in clinical development; these are orally active and increase levels of active GLP-1, which in turn increases insulin secretion and reduces glucagon secretion and ...
Medscape2d
DPP-4 Inhibitors -- An Update on Alogliptin
Alogliptin (NESINA), a dipeptidyl peptidase IV (DPP-4) inhibitor, was approved by the FDA on January 25, 2013 to improve blood sugar control in adults with type 2 diabetes. This drug had been ...
Too Old to Operate12d
GLP-1RAs and DPP-4Is Linked to Lower Cholangiocarcinoma Risk in T2DM
The following is a summary of “Association between incretin-based drugs and risk of cholangiocarcinoma among patients with ...
BioWorld15d
CSPC wins China clearance of new DPP-4 inhibitor
CSPC Pharmaceutical Group Ltd. on Jan. 13 gained the National Medical Products Administration’s approval of Shanzeping (prusogliptin tablets; DBPR-108) as a novel oral dipeptidyl peptidase-IV (DPP-4) ...
Renal & Urology News7d
SGLT2 Inhibitors Linked to Lower Rhabdomyolysis Risk in Statin Users
Use of SGLT2 inhibitors was associated with a lower risk for rhabdomyolysis than DPP-4 inhibitors among statin users. Sodium-glucose cotransporter-2 (SGLT2) inhibitor use is associated with a ...
Healio14d
GLP-1 receptor agonists tied to similar thyroid cancer risk as DPP-IV inhibitors
Adults with type 2 diabetes using a GLP-1 receptor agonist have a similar risk for developing thyroid cancer as those using a DPP-IV inhibitor, according to findings published in Thyroid. Researchers ...